Literature DB >> 10335549

A haplotype-based study of lithium responding patients with bipolar affective disorder on the Faroe Islands.

H Ewald1, A G Wang, M Vang, O Mors, M Nyegaard, T A Kruse.   

Abstract

The Faroe Islands are a small group of islands in the North Atlantic Ocean, situated between Norway, Iceland and Scotland. The origin of the population is thought to be a mixture of Norwegian, Danish and British. The islands were populated at the same time as Iceland, i.e. around 1100 years ago, and the size of the population was around, and occasionally below, 4000 inhabitants until 1800, after which it increased to its present-day level of around 45,000. The population is descended from Scandinavian and British ancestors. Because of the low number of founders and small size for many centuries, the Faroese population is perhaps the most valuable European population for genetic mapping of complex disease genes. The present study searched for haplotype sharing on chromosome 18 among eight lithium responding patients with bipolar affective disorder related, on average, 6.2 generations ago, using 30 DNA markers. In order to obtain as homogeneous a sample as possible, strict inclusion criteria based on severity of phenotype, geography and treatment response, were applied. Evidence suggestive of increased haplotype sharing on the distal part of chromosome 18q23 in the region implicated by Freimer and co-workers was found. However, methods of genetic analysis which might provide a conclusive result are not yet available.

Entities:  

Mesh:

Year:  1999        PMID: 10335549     DOI: 10.1097/00041444-199903000-00005

Source DB:  PubMed          Journal:  Psychiatr Genet        ISSN: 0955-8829            Impact factor:   2.458


  6 in total

1.  Pharmacogenomics of mood stabilizers in the treatment of bipolar disorder.

Authors:  Alessio Squassina; Mirko Manchia; Maria Del Zompo
Journal:  Hum Genomics Proteomics       Date:  2010-08-03

Review 2.  Long-term responsiveness to lithium as a pharmacogenetic outcome variable: treatment and etiologic implications.

Authors:  Firoza Mamdani; Iris Jaitovich Groisman; Martin Alda; Gustavo Turecki
Journal:  Curr Psychiatry Rep       Date:  2003-12       Impact factor: 5.285

Review 3.  Role of lithium augmentation in the management of major depressive disorder.

Authors:  Michael Bauer; Mazda Adli; Roland Ricken; Emanuel Severus; Maximilian Pilhatsch
Journal:  CNS Drugs       Date:  2014-04       Impact factor: 5.749

Review 4.  Lithium in the treatment of bipolar disorder: pharmacology and pharmacogenetics.

Authors:  M Alda
Journal:  Mol Psychiatry       Date:  2015-02-17       Impact factor: 15.992

5.  Lithium: a key to the genetics of bipolar disorder.

Authors:  Cristiana Cruceanu; Martin Alda; Gustavo Turecki
Journal:  Genome Med       Date:  2009-08-19       Impact factor: 11.117

Review 6.  Genetic influences on response to mood stabilizers in bipolar disorder: current status of knowledge.

Authors:  Janusz K Rybakowski
Journal:  CNS Drugs       Date:  2013-03       Impact factor: 5.749

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.